Clinical data | |
---|---|
Trade names | Ferriprox |
AHFS/Drugs.com | Monograph |
MedlinePlus | a612016 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Iron chelator[2] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Glucuronidation |
Elimination half-life | 2 to 3 hours |
Excretion | Kidney (75 to 90% in 24 hours) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C7H9NO2 |
Molar mass | 139.154 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Deferiprone, sold under the brand name Ferriprox among others, is a medication used to treat iron overload due to blood transfusions in thalassaemia major.[2][4] It is taken by mouth.[5] Evidence supports improved blood markers but not symptoms or survival.[4]
Common side effects include red-brown urine, nausea, abdominal pain, and vomiting.[2] Other side effects may include low white blood cells, infection, and prolonged QT.[2][4] Use in pregnancy may harm the baby.[4] It is an iron chelator.[2]
Deferiprone became commercially available in 1994.[6] It was initially approved in Europe and Asia.[7] It is on the World Health Organization's List of Essential Medicines as an alternative to deferasirox.[8] It is available as a generic medication.[5] This was followed by approval in the United States in 2011.[4] In the United Kingdom 100 tablets of 500 mg costs the NHS about £130.[5] In the United States this amount costs about 7,500 USD.[9]
References
edit- ^ a b "Deferiprone (Ferriprox) Use During Pregnancy". Drugs.com. 30 March 2020. Archived from the original on 26 October 2020. Retrieved 20 May 2020.
- ^ a b c d e f g h "Ferriprox EPAR". European Medicines Agency (EMA). Archived from the original on 14 August 2020. Retrieved 20 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Ferriprox 100 mg/ml oral solution - Summary of Product Characteristics (SmPC)". (emc). 26 November 2019. Archived from the original on 7 August 2020. Retrieved 20 May 2020.
- ^ a b c d e f "Deferiprone Monograph for Professionals". Drugs.com. Archived from the original on 11 June 2021. Retrieved 21 December 2021.
- ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1075. ISBN 978-0857114105.
- ^ Staff. "Cipla's History". Cipla. Archived from the original on 2015-10-27.
- ^ Savulescu J (February 2004). "Thalassaemia major: the murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ "Ferriprox Prices, Coupons and Patient Assistance Programs". Retrieved 22 December 2021.